Other

AbbVie cites tax break as a Shire deal motivator

U.S. drugmaker AbbVie sees a compelling tax break behind its roughly $46 billion bid to buy British counterpart Shire, and it expects the deal to expand Shire's global reach as well.

Jun 25, 2014
popularity not rated yet | comments 0

Takeover target Shire promises strong growth

Takeover target Shire on Monday highlighted its potential as a standalone drugmaker, offering investors a rosy projection of its earnings potential that it believes is not reflected in the acquisition proposal made by U.S.-based ...

Jun 23, 2014
popularity not rated yet | comments 0